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ABSTRACT:
The capacity of breast cancer cells to form mammospheres in non-adherent 
serum-free culture is used as a functional characteristic of the self-renewing stem-
like cell population. The present studies demonstrate that silencing expression of 
the MUC1-C oncoprotein inhibits growth of luminal MCF-7 and HER2-overexpressing 
SKBR3 breast cancer cells as mammospheres. We also show that triple-negative MDA-
MB-468 breast cancer cells are dependent on MUC1-C for growth as mammospheres 
and tumor xenografts. Similar results were obtained when MUC1-C function was 
inhibited by expression of a MUC1-C(CQCAQA) mutant. Moreover, treatment with 
the MUC1-C inhibitor GO-203, a cell penetrating peptide that binds to the MUC1-C 
cytoplasmic domain and blocks MUC1-C function, confirmed the importance of this 
target for self-renewal. The mechanistic basis for these findings is supported by the 
demonstration that MUC1-C activates NF-κB, occupies the IL-8 promoter with NF-κB, 
and induces IL-8 transcription. MUC1-C also induces NF-κB-dependent expression of 
the IL-8 receptor, CXCR1. In concert with these results, targeting MUC1-C with GO-
203 suppresses IL-8/CXCR1 expression and disrupts the formation of established 
mammospheres. Our findings indicate that MUC1-C contributes to the self-renewal of 
breast cancer cells by activating the NF-κBIL-8/CXCR1 pathway and that targeting 
MUC1-C represents a potential approach for the treatment of this population.  
INTRODUCTION
Normal tissues contain stem cell populations that 
renew through asymmetrical division and give rise to 
progenitors committed to functional differentiation [1]. 
Cancer stem-like cells are similarly capable of self-
renewal and have the capacity for generating diverse 
progeny that comprise the tumor [1, 2]. Stem-like 
cells from hematologic malignancies and solid tumors 
have  thus  been  defined  in  part  by  their  self-renewal 
and tumor-initiating potential [3]. Nonetheless, debate 
remains  about  the  definition  of  cancer  stem-like  cells 
as a result of their heterogeneity and plasticity [4, 5]. 
In this context, cell surface markers, such as CD44 and 
CD133, have been used to isolate subsets enriched for 
stem-like cells in solid tumors [5]. In addition, aldehyde 
dehydrogenase (ALDH) activity has been a focus of 
study as a marker for both normal and cancer stem cells 
[6]. Indeed, many of these markers are not exclusively 
expressed by cancer stem-like cells and the available 
evidence indicates that there is considerable phenotypic 
heterogeneity within these populations [4, 5]. With 
regard to functional characteristics, a hallmark of cancer 
stem-like cells is their relative resistance to apoptosis in 
the response to genotoxic stress induced by anti-cancer 
drugs and radiation [7]. Moreover, cancer stem-like cells 
have been characterized by their ability to undergo the 
epithelial-mesenchymal transition (EMT), a process that 
endows more differentiated epithelial cells with stem 
cell characteristics [8]. The induction of EMT results Oncotarget 2623 www.impactjournals.com/oncotarget
in both the acquisition of mesenchymal traits necessary 
for invasion and metastases, and the expression of CSC 
markers [8]. EMT also increases the capacity of mammary 
epithelial cells to form mammospheres in non-adherent 
serum-free culture [8], a characteristic that is dependent 
on the presence of self-renewing stem cells [9, 10]. The 
capacity for mammosphere formation has thus emerged 
as another hallmark of the breast cancer stem-like cell [9]. 
From a mechanistic standpoint, NF-κB signaling has been 
linked to self-renewal, mammosphere formation and breast 
cancer-initiating cells [11-13]. In addition, interleukin-8 
(IL-8), an inflammatory cytokine that is upregulated in 
breast cancer and is associated with a poor prognosis [14], 
has been identified as an important regulator of EMT, 
stem-like cell activity and mammosphere formation [15-
18].
Mucin 1 (MUC1) is a heterodimeric transmembrane 
protein that is aberrantly overexpressed in human breast 
cancers as a result in part of MUC1 gene amplification and 
dysregulation of its transcription [19]. The functional role 
of MUC1 in tumorigenesis was advanced by the finding 
that MUC1 undergoes autocleavage into two subunits, 
which in turn form a stable non-covalent heterodimer 
[19]. The extracellular N-terminal subunit (MUC1-N) is 
the mucin component of the heterodimer and is tethered 
to the cell surface in a complex with the transmembrane 
C-terminal subunit (MUC1-C) [19]. MUC1-C consists of a 
58-amino acid (aa) extracellular domain, a transmembrane 
region and a 72-aa cytoplasmic tail [19]. MUC1-C 
interacts with receptor tyrosine kinases (RTKs), such as 
EGFR and HER2, at the cell membrane and contributes to 
their activation [19, 20]. In this way, targeting MUC1-C 
with silencing downregulates p-HER2 activation in 
HER2-overexpressing breast cancer cells [20]. Moreover, 
inhibition of MUC1-C with GO-203, a cell penetrating 
peptide that binds to the MUC1-C cytoplasmic domain 
at the CQC motif and blocks MUC1-C function [21, 22], 
suppresses p-HER2 activation [20]. MUC1-C has also 
been linked to regulation of downstream RTK signaling, 
such as the PI3KAKT and MEKERK pathways [19, 
20, 23]. In addition, MUC1-C is imported into the nucleus 
by importin-β, where it interacts with transcription factors 
and contributes to their transactivating function [19, 24]. 
In this regard, MUC1-C associates with NF-κB p65 and 
induces activation of the ZEB1 gene by a NF-κB-mediated 
mechanism  [25].  In  turn,  ZEB1  suppresses  miR-200c 
expression and thereby induces EMT and cellular invasion 
by a MUC1-C-mediated mechanism [25]. In addition, 
recent studies have shown that MUC1-C interacts with 
the CCAAT/enhancer-binding protein β (C/EBPβ) on the 
ALDH1A1 gene promoter and induces C/EBPβ-mediated 
ALDH1A1 expression [23]. The available evidence thus 
links MUC1-C to the induction of EMT [25] and ALDH 
activity [23], both characteristics of breast cancer stem-
like cell populations. Other studies of breast cancer cells 
have demonstrated that MUC1 is detectable in “side 
populations” that express the ABCG2 transporter, which 
has been used as marker of stem/progenitor cells [26]. 
Overexpression of MUC1, as found in breast cancer cells, 
is also associated with resistance to apoptosis in response 
to genotoxic anti-cancer agents [27]. One study has 
demonstrated that MUC1 expression is increased in breast 
cancer cells that form mammospheres [28]; whereas, 
another publication reported that MUC1 is decreased 
under these conditions of anchorage-independent growth 
[29]. Of relevance to the present work, there is no 
available information that addresses whether MUC1-C is 
involved in mammosphere formation or in activation of 
the IL-8 pathway that contributes to the growth of breast 
cancer cells as spheres. 
The present studies demonstrate that MUC1-C is 
upregulated under nonadherent culture conditions, which 
select for self-renewing breast cancer cells. The results 
further demonstrate that silencing MUC1-C blocks the 
capacity of luminal, HER2-overexpressing and triple-
negative breast cancer cells to form mammospheres. 
Targeting MUC1-C homodimerization by expression of a 
MUC1-C(CQCAQA) mutant or the MUC1-C inhibitor 
GO-203 also blocks self-renewal of breast cancer cells. 
The mechanistic basis for these results is supported by the 
demonstration that MUC1-C activates NF-κB and thereby 
expression of IL-8 and CXCR1. Our findings indicate that 
targeting MUC1-C represents an approach to inhibit the 
self-renewal capacity of breast cancer cells. 
RESULTS
MUC1-C expression is upregulated in MCF-7 cell 
mammospheres. 
To assess the potential involvement of MUC1-C 
in conferring anchorage-independent growth, luminal 
ER+ MCF-7 breast cancer cells were established as 
mammospheres and serially passaged for three generations 
(M1 to M3) (Fig. 1A). MUC1-C expression was found 
to be substantially upregulated in M1, M2 and M3 
mammospheres as compared to that in MCF-7 cells grown 
as an adherent monolayer (Fig. 1B). In concert with the 
demonstration that MUC1-C activates ERKC/EBPβ 
signaling and induction of ALDH1A1 [23], we found 
activation of this pathway in MCF-7 mammospheres as 
evidenced by increased p-ERK, p-C/EBPβ and ALDH1A1 
levels (Fig. 1C). In addition, the upregulation of MUC1-C 
expression in MCF-7 mammospheres was associated with 
increases in aldefluor activity (Fig. 1D). Based on these 
findings, we silenced MUC1-C in MCF-7 cells to assess 
its functional role in sphere formation (Fig. 1E). Notably, 
MUC1-C  silencing  resulted  in  a  significant  reduction 
in mammosphere formation as indicated by marked 
decreases in both sphere size (Fig. 1F, left) and sphere Oncotarget 2624 www.impactjournals.com/oncotarget
forming efficiency (SFE) (Fig. 1F, right), indicating that 
MUC1-C is of functional importance for growth of breast 
cancer cells under anchorage-independent conditions. 
MUC1-C confers MCF-7 mammosphere 
formation.
To further address the notion that MUC1-C 
regulates mammosphere formation, we generated MCF-
7 cells that stably overexpress the MUC1-C subunit 
(Fig. 2A). MUC1-C overexpression had little effect on 
M1 mammosphere size (Fig. 2B, left), but significantly 
increased SFE from 3-4% to over 15% (Fig. 2B, right). 
MCF-7/MUC1-C cells also generated M2 and M3 
mammospheres that were somewhat more diffuse (Fig. 
2C) than that observed with MCF-7 cells (Fig. 1A), a 
finding that has been attributed to the development of 
EMT characteristics [30]. Adherent MCF-7/MUC1-C cells 
exhibit upregulation of the ERKC/EBPβALDH1A1 
pathway [23]. Similar findings were observed in the MCF-
7/MUC1-C cells grown as mammospheres as supported 
by increased p-C/EBPβ and ALDH1A1 levels (Fig. 2D). 
To determine whether MUC1-C-induced ALDH1 activity 
contributes to mammosphere formation, we silenced 
ALDH1A1 in MCF-7/MUC1-C cells (Fig. 2E). Of note, 
downregulation of ALDH1A1 expression had no apparent 
effect on mammosphere size (Fig. 2F, left) or SFE (Fig. 
2F, right), indicating that MUC1-C confers non-adherent 
growth by an ALDH1A1-independent mechanism.
HER2-overexpressing and triple-negative breast 
cancer cells are dependent on MUC1-C for 
mammosphere formation.
To extend these findings with luminal MCF-7 cells 
to other breast cancer cell types, we first studied HER2-
overexpressing SKBR3 cells. As found for MCF-7 cells, 
stable silencing of MUC1-C in SKBR3 cells (Fig. 3A) 
was associated with a marked decrease in mammosphere 
size (Fig. 3B, left) and SFE (Fig. 3B, right). Silencing 
MUC1-C in triple-negative (ER-/PR-/HER2-) MDA-
MB-468  cells  (Fig.  3C)  also  resulted  in  substantial 
suppression of mammosphere size (Fig. 3D, left) and 
SFE (Fig. 3D, right), indicating that these effects of 
silencing MUC1-C are independent of breast cancer cell 
subtype. Similar results were obtained when MUC1-C 
Figure 1: Silencing MUC1 expression attenuates formation of MCF-7 cell mammospheres. A. Representative phase contrast 
microscopy images are shown for MCF-7 mammospheres that were serially passaged for three generations (M1 to M3). Bar represents 
50 microns. B. Lysates of MCF-7 cells cultured as an adherent monolayer or as M1, M2 and M3 mammospheres were immunoblotted 
with the indicated antibodies. C. Lysates of MCF-7 cells cultured as an adherent monolayer or as mammospheres were immunoblotted 
with the indicated antibodies. D. MCF-7 cells grown as monolayers and as mammospheres were incubated with the ALDH substrate 
(BAAA) and the ALDH1 inhibitor (DEAB). The percentage of aldefluor-positive cells is included in the panels. E. MCF-7 cells were 
infected with lentiviruses to stably express a control scrambled shRNA (CshRNA) or a MUC1 shRNA. Lysates from the MCF-7/CshRNA 
and MCF-7/MUC1shRNA cells were immunoblotted with the indicated antibodies. F. Images are shown for MCF-7/CshRNA and MCF-
7/MUC1shRNA cells grown as mammospheres (left). Bar represents 50 microns. The percentage sphere forming efficiency (SFE) is 
expressed as the mean±SD of three determinations (right).Oncotarget 2625 www.impactjournals.com/oncotarget
was  downregulated  in  MDA-MB-468  cells  using  a 
different shRNA (Supplemental Figs. S1A and B), further 
indicating that the findings are not the result of shRNA off-
target effects. Silencing MUC1-C in MDA-MB-468 cells 
causes downregulation of the ERKC/EBPβALDH1 
pathway and loss of ALDH1 activity [23]. We therefore 
silenced ALDH1A1 in MDA-MB-468 cells to assess their 
dependence on ALDH1A1 for sphere formation (Fig. 3E). 
As found for MCF-7 cells, the results demonstrate that 
MDA-MB-468 mammosphere formation is conferred by a 
MUC1-C-dependent, ALDH1A1-independent mechanism 
(Fig. 3F, left and right).
Targeting MUC1-C homodimerization abrogates 
mammosphere formation.
The MUC1-C cytoplasmic domain contains a CQC 
motif that is necessary for the formation of MUC1-C 
homodimers and thereby the MUC1-C oncogenic 
function (Fig. 4A) [19]. To search for further evidence 
linking MUC1-C to mammosphere formation, we 
stably expressed a MUC1-C(CQCAQA) mutant in 
MDA-MB-468 cells (Fig. 4B). MUC1-C(CQCAQA) 
expression was associated with marked suppression 
of MDA-MB-468 mammosphere formation (Fig. 4C), 
indicating that MUC1-C homodimerization is necessary 
for conferring anchorage-independent growth. Previous 
work showed that MUC1-C homodimerization is inhibited 
by the cell-penetrating peptide, GO-203, which contains a 
poly-Arg transduction domain linked to CQCRRKN and 
binds to endogenous MUC1-C at the CQC motif [21](Fig. 
4A). Notably, GO-203 treatment blocked the formation of 
MDA-MB-468 mammospheres (Fig. 4D). By contrast, the 
CP-2 peptide, which includes AQARRKN and is not active 
in targeting the MUC1-C CQC motif (Fig. 4A) [21], had 
no apparent effect on sphere formation (Fig. 4D, left and 
right). GO-203, but not CP-2, treatment for 36 h was also 
highly effective in disrupting established MDA-MB-468 
mammospheres (Fig. 4E). Moreover, established SKBR3 
mammospheres were disrupted by targeting MUC1-C with 
GO-203 (Fig. 4F), providing further evidence that supports 
the importance of MUC1-C in conferring anchorage-
independent growth and self-renewal. 
MUC1-C induces mammosphere formation by an 
NF-κB-dependent mechanism. 
 Activation of the NF-κB pathway has been linked to 
breast cancer-initiating cell activity [11-13]. Other studies 
have shown that aberrant expression of MUC1-C activates 
NF-κB signaling [24, 31]. Therefore, to determine whether 
MUC1-C confers mammosphere formation through 
Figure 2: Overexpression of MUC1-C induces MCF-7 mammosphere formation. A. MCF-7 cells were infected with 
lentiviruses to stably express a control vector or MUC1-C. Lysates from the MCF-7/vector and MCF-7/MUC1-C cells were immunoblotted 
with the indicated antibodies. B. Representative images are shown for MCF-7/vector and MCF-7/MUC1-C mammospheres (left). The 
percentage SFE is expressed as the mean±SD of three determinations (right). Bar represents 50 microns. C. Representative images are 
shown for MCF-7/MUC1-C cells grown as M1, M2 and M3 mammospheres.  Bar represents 50 microns. D. Lysates of MCF-7/vector 
and MCF-7/MUC1-C cells grown as mammospheres were immunoblotted with the indicated antibodies. E. MCF-7/MUC1-C cells were 
infected with lentiviruses that stably express a control scrambled shRNA (CshRNA) or an ALDH1A1 shRNA. Lysates from MCF-7/ 
MUC1-C/ CshRNA and MCF-7/MUC1-C/ALDH1A1shRNA cells were immunoblotted with the indicated antibodies. F. Representative 
images are shown for MCF-7/MUC1-C/CshRNA and MCF-7/MUC1-C/ALDH1A1shRNA cells grown as mammospheres (left).  Bar 
represents 50 microns. The percentage SFE is expressed as the mean±SD of three determinations (right). Oncotarget 2626 www.impactjournals.com/oncotarget
induction of NF-κB, we first asked if overexpression of 
MUC1-C in MCF-7 cells is associated with an increase 
in  NF-κB  activity.  Using  an  NF-κB-driven  promoter-
reporter, we found a significant increase in NF-κB activity 
in MCF-7/MUC1-C cells as compared to that obtained 
in MCF-7/vector cells (Fig. 5A). Treatment of MCF-7/
MUC1-C cells with the NF-κB inhibitor BAY11-7085 
was associated with suppression of NF-κB activity (Fig. 
5B). Moreover, MUC1-C-induced MCF-7 mammosphere 
formation  was  inhibited  by  BAY11-7085  (Figs.  5C, 
left and right), indicating that MUC1-C induces NF-κB 
activity and thereby anchorage-independent growth. 
With regard to downstream signaling, NF-κB has been 
shown to confer stemness and the formation of spheres 
by upregulating expression of IL-8 [32, 33]. In this 
context, we observed marked increases in IL-8 mRNA 
levels in MCF-7/MUC1-C, as compared to MCF-7/
vector, cells (Fig. 5D) that was suppressed in MCF-7/
MUC1-C cells by inhibition of NF-κB with BAY11-7085 
(Fig. 5E). MUC1-C binds directly to NF-κB p65 and 
promotes recruitment of MUC1-C/NF-κB complexes to 
the promoters of NF-κB target genes [24]. By extension, 
ChIP analysis of the IL-8 promoter, which contains an NF-
κB binding site, demonstrated that NF-κB p65 occupancy 
is increased in MCF-7/MUC1-C cells (Fig. 5F) and that, 
in re-ChIP studies, MUC1-C is detectable on the IL-8 
Figure 3: HER2-overexpressing and triple-negative breast cancer cells are dependent on MUC1-C for mammosphere 
formation. A.SKBR3 cells were infected with lentiviruses stably expressing a CshRNA or MUC1shRNA. Lysates from SKBR3/CshRNA 
and SKBR3/MUC1shRNA cells were immunoblotted with the indicated antibodies. B. Representative images are shown of SKBR3/
CshRNA and SKBR3/MUC1shRNA cells grown in mammosphere culture medium (left). Bar represents 100 microns. The percentage 
SFE is expressed as the mean±SD of three determinations (right). C. MDA-MB-468 cells were infected with lentiviruses stably expressing 
CshRNA or MUC1shRNA. Lysates of MDA-MB-468/CshRNA and MDA-MB-468/MUC1shRNA cells were immunoblotted with the 
indicated antibodies. D. Representative images are shown of MDA-MB-468/CshRNA and MDA-MB-468/MUC1shRNA cells grown in 
mammosphere culture medium (left). Bar represents 100 microns. The percentage SFE is expressed as the mean±SD of three determinations 
(right). E. MDA-MB-468 cells were infected with lentiviruses that stably express a control CshRNA or an ALDH1A1 shRNA. Lysates 
were immunoblotted with the indicated antibodies. F. Representative images are shown of MDA-MB-468/CshRNA and MDA-MB-468/
ALDH1A1shRNA cells grown as mammospheres (left). Bar represents 100 microns. The percentage SFE is expressed as the mean±SD of 
three determinations (right).  Oncotarget 2627 www.impactjournals.com/oncotarget
promoter  with  NF-κB  p65  (Fig.  5G).  These  findings 
provided support for a mechanism in which MUC1-C 
activates NF-κB and thereby induces IL-8 expression and 
mammosphere formation. 
Silencing MUC1-C suppresses IL-8 mRNA levels.
Activation of HER2 in breast cancer cells promotes 
stemness and sphere formation by upregulation of NF-κB 
and IL-8 signaling [34, 35]. Moreover, IL-8 plays a critical 
role in the acquisition and maintenance of EMT [17]. Our 
observation that silencing MUC1-C in SKBR3 cells blocks 
mammosphere formation (Figs. 3B and C) thus prompted 
studies to evaluate NF-κB activation and IL-8 expression 
in this model. As compared to SKBR3/CshRNA cells, 
downregulation  of  MUC1-C  in  SKBR3/MUC1shRNA 
cells was associated with suppression of NF-κB activity 
(Fig. 6A) and NF-B occupancy on the IL-8 promoter 
(Fig. 6B). Silencing MUC1-C in SKBR3 cells was also 
associated with decreases in IL-8 mRNA levels (Fig. 6C). 
To extend this line of investigation to MDA-MB-468 cells, 
we found that silencing MUC1-C similarly suppresses 
NF-κB activity (Fig. 6D), NF-κB occupancy on the IL-8 
promoter (Fig. 6E) and IL-8 mRNA levels (Fig. 6F). We 
also found that MDA-MB-468 cells stably silenced for 
NF-κB p65 (Supplemental Fig. S2A) exhibit decreases 
in IL-8 expression (Supplemental Fig. S2B). Moreover, 
as  shown  for  MDA-MB-468/MUC1shRNA  cells, 
silencing NF-κB p65 was associated with suppression of 
mammosphere formation (Supplemental Fig. S2C, left 
and right). These findings thus provided further support 
for activation of a MUC1-CNF-κBIL-8 pathway. 
Targeting MUC1-C downregulates both IL-8 and 
CXCR1 expression. Other work has shown that NF-
κB  induces  expression  of  the  IL-8  receptor,  CXCR1 
[36]. In this regard and like IL-8, CXCR1 expression 
was increased in MCF-7/MUC1-C cells (Fig. 7A, left). 
Additionally, MUC1-C-induced increases in CXCR1 
expression  were  inhibited  by  BAY11-7085  (Fig.  7A, 
Figure 4: Targeting MUC1-C homodimerization suppresses mammosphere formation. A. Schema of the MUC1-C subunit 
(ED, extracellular domain; TM, transmembrane region) and the amino acid (aa) sequence of the cytoplasmic domain (CD). Highlighted is 
the CQC motif that is necessary for MUC1-C homodimerization. CQC has been mutated to AQA in the MUC1-C(AQA) vector. The CQC 
motif is the target of the GO-203 peptide. The control CP-2 peptide differs from GO-203 in that the critical CQC motif has been altered to 
AQA. B. MDA-MB-468 cells expressing a control vector or a MUC1-C(CQCAQA) mutant were analyzed for MUC1-C mRNA levels by 
qRT-PCR. The results are expressed as relative MUC1-C mRNA levels (mean±SD of three determinations) as compared with that obtained 
for GAPDH (vector cells assigned a value of 1). C. Representative images are shown of MDA-MB-468/vector and MDA-MB-468/MUC1-
C(AQA) cells grown in mammosphere culture medium (left). Bar represents 100 microns. The percentage SFE is expressed as the mean±SD 
of three determinations (right). D. MDA-MB-468 cells were suspended in mammosphere culture medium containing 5 μM CP-2 or 5 μM 
GO-203. Images taken after 48 h are shown for the CP-2- and GO-203-treated cells (left).  Bar represents 100 microns. The percentage 
SFE is expressed as the mean±SD of three determinations (right). E. MDA-MB-468 cells were established as mammospheres (left) and 
then treated with 5 μM GO-203 (middle) or 5 μM CP-2 (right) for 36 h. Bar represents 100 microns. F. SKBR3 cells were established as 
mammospheres (left) and then treated with 5 μM GO-203 (middle) or 5 μM CP-2 (right) for 24 h. Bar represents 100 microns.  Oncotarget 2628 www.impactjournals.com/oncotarget
right),  supporting  an  NF-κB-mediated  mechanism. 
Blocking  MUC1-C  homodimerization  with  GO-203 
disrupts the interaction with NF-κB p65 and activation 
of the NF-κB pathway [24]. In this regard, treatment of 
MCF-7/MUC1-C cells with GO-203 was associated with 
downregulation of both IL-8 (Fig. 7B, left) and CXCR1 
(Fig. 7B, right). GO-203, but not CP-2, treatment was 
also associated with disruption of established MCF-7/
MUC1-C mammospheres (Fig. 7C). In concert with 
these findings and the downregulation of IL-8 (Fig. 6F), 
silencing MUC1-C in MDA-MB-468 cells was associated 
with decreases in CXCR1 mRNA levels (Fig. 7D). Similar 
results were obtained in MDA-MB-468 cells silenced 
for NF-κB p65 (Supplemental Fig. S3), confirming the 
induction of CXCR1 expression by an NF-κB-dependent 
mechanism. To extend these observations, we investigated 
the effects of silencing MUC1-C on tumorigenicity of 
MDA-MB-468 cells. In concert with a decrease in the 
capacity for mammosphere formation, growth of MDA-
MB-468/MUC1shRNA  cells  as  tumor  xenografts  was 
substantially inhibited as compared to that obtained for 
MDA-MB-468/CshRNA cells (Fig. 7E, left and right). 
qRT-PCR analysis of the MDA-MB-468 cells growing 
as tumors further demonstrated that silencing MUC1-C 
results in decreased expression of IL-8 (Fig. 7F, left) 
and CXCR1 (Fig. 7F, right). These findings collectively 
indicated that targeting MUC1-C suppresses NF-
κBIL-8/CXCR1 signaling and thereby mammosphere 
formation and tumorigenicity.
DISCUSSION
MUC1 is aberrantly overexpressed in luminal, 
HER2+ and basal-like triple-negative breast cancers 
[19, 37] as a result in part of MUC1 gene alterations and 
dysregulation of transcription [19]. The MUC1-C subunit 
Figure 5: MUC1-C induces mammosphere formation by an NF-κB-dependent mechanism. A. MCF-7/vector and MCF-
7/MUC1-C cells were cotransfected with p-NF-κB/Luc and control pRL-TK plasmids. Luciferase activity was measured 48 h after 
transfection. Results are expressed as relative luciferase activity (mean±SD of three determinations) compared to that obtained with MCF-
7/vector cells (assigned a value of 1). B. MCF-7/MUC1-C cells were cotransfected with the p-NF-κB/Luc and pRL-TK plasmids. After 
48 h, the transfected cells were left untreated (Control) and treated with DMSO as vehicle or with 5 μM BAY11-7085 for an additional 
12 h. Results are expressed as relative luciferase activity (mean±SD of three determinations) as compared to that obtained for the control 
untreated cells (assigned a value of 1). C. MCF-7/MUC1-C cells were suspended in mammosphere culture medium and left untreated 
(Control) or treated with DMSO or 5 μM BAY11-7085. Cells were imaged after 5 days (left). Bar represents 50 microns. The percentage 
SFE is expressed as the mean±SD of three determinations (right). D and E. MCF-7/vector and MCF-7/MUC1-C cells were analyzed 
for IL-8 mRNA levels by qRT-PCR (vector cells assigned a value of 1). (D). MCF-7/MUC1-C cells were treated with DMSO or 5 μM 
BAY11-7085 for 12 h (E). The results are expressed as relative IL-8 mRNA levels (mean±SD of three determinations) as compared with 
that obtained for GAPDH (BAY11-treated cells assigned a value of 1). F. Schematic representation of the IL-8 promoter with positioning 
of the NF-κB site. Soluble chromatin from MCF-7/vector and MCF-7/MUC1-C cells was precipitated with anti-NF-κB or a control IgG. 
The final DNA samples were amplified by qPCR with pairs of primers for the NF-κB binding region (NBR; -117 to –29) or a control region 
(CR; -4840 to –4775). The results (mean±SD of three determinations) are expressed as the relative fold enrichment compared with that 
obtained with the IgG control (vector cells assigned a value of 1). G. Soluble chromatin from MCF-7/vector and MCF-7/MUC1-C cells 
was precipitated with anti-NF-κB, released and reimmunoprecipitated with anti-MUC1-C. The final DNA samples were amplified by qPCR 
with pairs of primers for the IL-8 promoter NBR and CR. The results (mean±SD of three determinations) are expressed as the relative fold 
enrichment compared with that obtained with the IgG control (vector cells assigned a value of 1).  Oncotarget 2629 www.impactjournals.com/oncotarget
has also been linked to ER function [38-40] and HER2 
activation [20] in breast cancer cells. Strikingly, however, 
little is known about whether MUC1-C is of importance 
for the growth and survival of breast cancer cells that 
have the capacity for self-renewal. The present studies 
demonstrate that growth of luminal MCF-7 breast cancer 
cells as mammospheres, which enriches for self-renewing 
breast cancer cells that survive anoikis under nonadherent 
conditions [9, 10], is associated with substantial 
upregulation of MUC1-C expression. Consistent with 
a potential functional role, silencing MUC1-C in MCF-
7 cells decreased mammosphere formation. In addition, 
overexpression of MUC1-C in this model increased sphere 
forming  efficiency.  Anchorage-independent  growth  is 
associated with induction of ALDH1 activity, supporting 
ALDH1 as a marker of human mammary stem cells 
[41]. Additionally, recent studies in MCF-7 and other 
breast cancer cells have shown that MUC1-C increases 
ALDH1A1 expression [23], raising the possibility 
that MUC1-C induces ALDH1 activity and thereby 
mammosphere formation. However, silencing ALDH1A1 
in MCF-7/MUC1-C cells had no apparent effect on 
mammosphere formation, indicating that MUC1-C confers 
mammosphere formation by an alternative mechanism 
(Fig. 7G). To provide further support for involvement of 
MUC1-C in self-renewal activity, we silenced MUC1-C in 
HER2+ SKBR3 and triple-negative MDA-MB-468 cells. 
Here  again,  downregulation  of  MUC1-C  significantly 
decreased the capacity of these breast cancer cells to 
form mammospheres. Silencing MUC1-C in MDA-
MB-468  cells  is  also  associated  with  suppression  of 
ALDH1 activity [23]. However, consistent with findings 
in MCF-7/MUC1-C cells, silencing ALDH1A1 in MDA-
MB-468 cells had little if any effect on mammosphere 
formation, indicating that increases in ALDH1A1 activity 
are dispensable for anchorage-independent growth (Fig. 
7G). Other work has shown that MUC1-C induces EMT 
in breast cancer cells by activating the ZEB1/miR-200c 
regulatory loop [25]. In this context, EMT increases 
the capacity of mammary epithelial cells to form 
mammospheres [8], providing an alternative mechanism 
by which MUC1-C could promote non-adherent growth 
Figure 6: Silencing MUC1-C in SKBR3 and MDA-MB-468 cells suppresses IL-8 expression. A. SKBR3/CshRNA and 
SKBR3/MUC1shRNA cells were cotransfected with p-NF-κB/Luc and control pRL-TK plasmids. Luciferase activity was measured 48 
h after transfection. Results are expressed as relative luciferase activity (mean±SD of three determinations) compared to that obtained 
with SKBR3/MUC1shRNA cells (assigned a value of 1). B. Soluble chromatin from SKBR3/CshRNA and SKBR3/MUC1shRNA cells 
was precipitated with anti-NF-κB or a control IgG. The final DNA samples were amplified by qPCR with pairs of primers for the NBR 
or CR. The results (mean±SD of three determinations) are expressed as the relative fold enrichment compared with that obtained with 
the IgG control (MUC1shRNA cells assigned a value of 1). C. SKBR3/CshRNA and SKBR3/MUC1shRNA cells were analyzed for 
IL-8 mRNA levels. The results are expressed as relative IL-8 mRNA levels (mean±SD of three determinations) as compared with that 
obtained for GAPDH (MUC1shRNA cells assigned a value of 1). D. MDA-MB-468/CshRNA and MDA-MB-468/MUC1shRNA cells were 
cotransfected with p-NF-κB/Luc and pRL-TK plasmids. Luciferase activity was measured 48 h after transfection. Results are expressed as 
relative luciferase activity (mean±SD of three determinations) compared to that obtained with MDA-MB-468/MUC1shRNA cells (assigned 
a value of 1). E. Soluble chromatin from MDA-MB-468/CshRNA and MDA-MB-468/MUC1shRNA cells was precipitated with anti-NF-
κB or a control IgG. The final DNA samples were amplified by qPCR with pairs of primers for the NBR or CR. The results (mean±SD 
of three determinations) are expressed as the relative fold enrichment compared with that obtained with the IgG control (MUC1shRNA 
cells assigned a value of 1). F. MDA-MB-468/CshRNA and MDA-MB-468/MUC1shRNA cells were analyzed for IL-8 mRNA levels. 
The results are expressed as relative IL-8 mRNA levels (mean±SD of three determinations) as compared with that obtained for GAPDH 
(MUC1shRNA cells assigned a value of 1). Oncotarget 2630 www.impactjournals.com/oncotarget
and survival (Fig. 7G). 
MUC1-C contributes to activation of the canonical 
NF-κB pathway [31]. MUC1-C also interacts directly 
with  NF-κB  p65  and  promotes  activation  of  NF-κB-
dependent  genes  [24].  Other  work  has  linked  NF-κB 
activation to mammosphere formation and breast cancer-
initiating activity [11-13, 34]. In this respect, we found 
that inhibition of MUC1-C-induced NF-κB activity is 
associated with suppression of self-renewal mammosphere 
formation, indicating that MUC1-C induces anchorage-
independent  growth  by  an  NF-κB-mediated  pathway. 
The available evidence supports involvement of NF-κB 
in conferring stemness and sphere formation by inducing 
IL-8 signaling [35, 36, 42]. Indeed, consistent with 
induction of the IL-8 pathway, MUC1-C increased NF-κB 
occupancy of the IL-8 promoter and inhibition of MUC1-C 
resulted in downregulation of IL-8 expression. The 
proximal promoter of the IL-8 gene has adjacent NF-κB- 
and C/EBP-binding sites that cooperate in transactivation 
[42, 43]. In addition, NF-κB and C/EBP physically form 
complexes on target gene promoters and cooperate in 
the activation of IL-8 transcription [44]. C/EBPβ plays 
an important role in mammary gland development by 
regulating stem cell repopulating activity [45]. Indeed, 
recent studies have shown that MUC1-C interacts with 
C/EBPβ, occupies the ALDH1A1 promoter with C/EBPβ 
and thereby contributes to upregulation of ALDH1A1 
expression [23]. Therefore, the present studies do not 
Figure 7: Targeting MUC1-C downregulates IL-8 and CXCR1 expression and blocks tumorigenicity. A. MCF-7/vector 
and MCF-7/MUC1-C cells were analyzed for CXCR1 mRNA levels by qRT-PCR (left). MCF-7/MUC1-C cells were treated with DMSO 
or 5 μM BAY11-7085 for 12 h (right). The results are expressed as relative CXCR1 mRNA levels (mean±SD of three determinations) as 
compared with that obtained for GAPDH (vector cells and BAY11-treated cells assigned a value of 1). B. MCF-7/MUC1-C cells were 
treated with 5 µM CP-2 or GO-203 for 48 h and then analyzed for IL-8 (left) and CXCR1 (right) mRNA levels by qRT-PCR. The results 
are expressed as relative CXCR1 mRNA levels (mean±SD of three determinations) as compared with that obtained for GAPDH (GO-203-
treated cells assigned a value of 1). C. MCF-7/MUC1-C cells were established as mammospheres (left) and then treated with 5 μM GO-203 
(middle) or 5 μM CP-2 (right) for 48 h. Bar represents 50 microns. D. MDA-MB-468/CshRNA and MDA-MB-468/MUC1shRNA cells 
were analyzed for CXCR1 mRNA levels. The results are expressed as relative CXCR1 mRNA levels (mean±SD of three determinations) 
as compared with that obtained for GAPDH (MUC1shRNA cells assigned a value of 1). E. MDA-MB-468/CshRNA (closed circles) and 
MDA-MB-468/MUC1shRNA (open circles) cells were injected subcutaneously in the flanks of female nude mice. Tumor volumes were 
determined on the indicated days after injection. The results are expressed as tumor volumes (mean±SEM for 3 mice) (left). Representative 
MDA-MB-468/CshRNA  and  MDA-MB-468/MUC1shRNA  tumors  were  excised  on  day  37  (right).  F.  MDA-MB-468/CshRNA  and 
MDA-MB-468/MUC1shRNA tumor cells were analyzed for IL-8 (left) and CXCR1 (right) mRNA levels by qRT-PCR. The results are 
expressed as relative mRNA levels (mean±SD of three determinations) as compared with that obtained for GAPDH (MUC1shRNA cells 
assigned a value of 1). G. Schema depicting MUC1-C-induced activation of NF-κB p65 and thereby induction of IL-8/CXCR1 expression 
and mammosphere formation. Targeting MUC1-C with (i) silencing, (ii) expressing a MUC1-C(CQCAQA) mutant, or (iii) GO-203 
treatment suppresses NF-κB activity, decreases IL-8/CXCR1 expression and inhibits mammosphere formation. MUC1-C also activates 
(i) NF-κB p65-mediated induction of ZEB1 and EMT [25], and (ii) ERKC/EBPβ signaling and ALDH1A1 expression [23]. Our results 
demonstrate that silencing ALDH1A1 has no detectable effect on mammosphere formation, indicating that the MUC1-CNF-κB and 
MUC1-CALDH1A1 pathways confer distinct functions.Oncotarget 2631 www.impactjournals.com/oncotarget
exclude the possibility that MUC1-C may further enhance 
IL-8 transcription by promoting interaction between NF-
κB p65 and C/EBPβ on the IL-8 promoter. Consistent with 
MUC1-C-induced activation of NF-κB and the presence of 
a functional NF-κB binding site on the CXCR1 promoter, 
we also found that MUC1-C drives CXCR1 expression by 
an NF-κB-dependent mechanism. These findings support 
a pathway in which MUC1-C activates NF-κB and induces 
IL-8 and CXCR1 expression, which in turn drives self-
renewal capacity and mammosphere formation (Fig. 7G). 
Thus, in this model, targeting MUC1-C is sufficient to 
suppress the IL-8/CXCR1 signaling pathway and decrease 
self-renewal. Other work has shown that that IL-6 can 
contribute to MCF-7 mammosphere formation [46] and 
IL-8-mediated survival [43]. Accordingly, additional 
studies will be needed to determine whether MUC1-C also 
contributes to the regulation of IL-6 expression in breast 
cancer cells.
MUC1-C forms complexes with HER2/HER3 at 
the breast cancer cell membrane and contributes to their 
activation [19, 20]. The MUC1-C cytoplasmic domain 
contains a CQC motif that is necessary and sufficient 
for the formation of MUC1-C homodimers, which are of 
importance for MUC1-C function [19]. Thus, targeting 
MUC1-C with silencing or by blocking the CQC motif 
in HER2+ breast cancer cells results in inhibition of 
p-HER2 activation and the downstream AKT pathway 
[20]. HER2 drives stem cell-like activity by AKTβ 
catenin signaling [47, 48] and through an interaction 
between HER2 and CXCR1/2 [18]. Therefore, the present 
finding that targeting MUC1-C in HER2+ SKBR3 cells 
inhibits mammosphere formation could be a consequence 
of p-HER2 downregulation. Nonetheless, we also found 
that silencing MUC1-C suppresses the formation of triple-
negative  MDA-MB-468  mammospheres.  In  addition, 
expression of the MUC1-C(CQCAQA) mutant blocked 
MDA-MB-468  sphere  formation,  indicating  that  the 
MUC1-C CQC motif and MUC1-C homodimerization 
are necessary for anchorage-independent growth. The 
formation of MUC1-C homodimers is also necessary for 
import of MUC1-C into the nucleus, where it interacts 
with  transcription  factors,  such  as  NF-κB  [19]. Thus, 
targeting MUC1-C homodimerization by treatment 
with inhibitors, such as GO-203, blocks MUC1-C-
induced  activation  of  the  NF-κB  pathway  [24],  and 
thereby induction of IL-8/CXCR1 expression and 
mammosphere formation. Previous studies with other cell-
penetrating peptides that bind to the MUC1-C CQC motif 
demonstrated that blocking MUC1-C homodimerization is 
effective in killing breast cancer cells growing in vitro and 
as tumor xenografts [49]. The present work extends these 
observations by demonstrating that silencing MUC1-C 
in MDA-MB-468 cells markedly inhibits tumorigenicity. 
These effects of targeting MUC1-C are associated with 
increases in reactive oxygen species (ROS) and the 
induction of late apoptosis/necrosis [49]. By extension, 
MUC1-C protects cells from increases in ROS associated 
with exposure to hypoxia and glucose deprivation [19]. 
Increasing evidence indicates that cancer stem-like cells 
maintain low ROS levels and that disruption of ROS 
defense mechanisms results in loss of their survival [50-
53]. In this way, dependence of breast cancer cell survival 
on activation of NF-κB, and thereby cytokine signaling 
that can further activate NF-κB in a positive feedback 
loop, may contribute to maintenance of ROS levels and 
self-renewal. Therefore, based on the present findings, 
targeting MUC1-C in breast cancer-initiating cells with 
downregulation of NF-κB activation could in turn disrupt 
redox balance and induce loss of self-renewal. 
Finally, a Phase I trial of GO-203 has been 
completed in patients with refractory solid tumors and, 
as a result, definition of a maximum tolerated dose for 
Phase II studies. The finding that targeting MUC1-C with 
GO-203 inhibits self-renewal of breast cancer stem-like 
cells supports further evaluation of GO-203 alone and in 
combination with other agents used for the treatment of 
breast cancer. In this way, GO-203 has been synergistically 
combined with tamoxifen [40], trastuzumab [20] and the 
cytotoxic drugs, taxol and doxorubicin [54], and therefore 
could be used clinically with these agents to more 
effectively treat the breast cancer stem-like, initiating cell 
population.  
METHODS
Cell culture. 
Human MCF-7 and MDA-MB-468 breast cancer 
cells were cultured in DMEM with 10% heat-inactivated 
fetal bovine serum (FBS), 100 units/ml penicillin, 100 
μg/ml  streptomycin,  and  2  mM  L-glutamine.  SKBR3 
breast cancer cells were grown in McCoy’s 5A medium 
containing  FBS,  antibiotics  and  glutamine.  MCF-7, 
MDA-MB-468 and SKBR3 cells were transduced with 
a lentiviral vector expressing a MUC1 shRNA (Sigma), 
a NF-κB p65 shRNA (Sigma) or, as a control, with a 
scrambled shRNA vector (CshRNA) as described [23]. 
MCF-7 cells were stably transfected with a control pHR-
CMV vector or one expressing MUC1-C [23]. Cells were 
treated with the MUC1-C inhibitor GO-203, the control 
CP-2 [20] or the NF-κB pathway inhibitor BAY11-7085 
(Santa Cruz Biotechnology).
Immunoprecipitation and immunoblotting.
Whole cell lysates were prepared in NP-40 lysis 
buffer and analyzed by immunoblotting with anti-
MUC1-C  (LabVision),  anti-NF-κB  p65  (Santa  Cruz 
Biotechnology)  and  anti-β-actin  (Sigma)  as  described 
[25]. Immune complexes were detected using horseradish Oncotarget 2632 www.impactjournals.com/oncotarget
peroxidase-conjugated secondary antibodies and enhanced 
chemiluminescence (GE Healthcare). 
Quantitative RT-PCR.
For qRT-PCR analysis, cDNA synthesis was 
performed with 1 μg total RNA using the Thermoscript 
RT-PCR system (Invitrogen). cDNA samples were 
amplified  using  the  SYBR  green  qPCR  assay  kit 
(Applied Biosystems) and the ABI Prism 7000 Sequence 
Detector (Applied Biosystems). Primers used for qRT-
PCR detection of IL-8 and CXCR1 mRNAs are listed 
in Supplemental Table S1. Statistical significance was 
determined by the Student’s t-test. 
NF-κB transcriptional activity. 
 Cells (5 x 105) growing in six-well plates were 
transfected in the presence of Superfect transfection 
reagent  (Qiagen)  with  (i)  1  µg  of  the  p-NF-κB-Luc 
plasmid containing NF-κB-activated sequences upstream 
to  the  luciferase  reporter  (pGL4.32/luc2P/NF-κB-RE/
Hygro; Promega) and (ii) 1 ng of a control reporter 
plasmid (pRL-TK) containing the Renilla gene under 
control of the TK promoter. After 48 h, the cells were 
harvested and lysed in passive lysis buffer. Luciferase 
activity was analyzed using the Dual Luciferase Assay 
System (Promega). Relative luciferase activity is reported 
as the fold-induction after normalization for transfection 
efficiency.
Measurement of ALDH activity. 
The Aldefluor assay kit (Stem Cell Technologies) 
was used for determination of ALDH enzymatic 
activity. Cells were suspended in aldefluor assay buffer 
and incubated with the ALDH enzyme substrate, 
BODIPY-aminoacetaldehyde  (BAAA),  for  40  min 
at 37°C. As a control, cells were also treated with 
diethylaminobenzaldehyde (DEAB), an inhibitor of ALDH 
enzyme activity. Fluorescence was determined using a BD 
Biosciences LSRFortessa flow cytometer and analyzed 
using FACSDiva software (BD Biosciences). Statistical 
significance was determined by the Student’s t-test.
Mammosphere culture.
Single-cell suspensions were cultured in 
MammoCult™ Human Medium Kit (Stem Cell 
Technologies) at a density of 2,000 to 10,000 cells 
per well of a 6-well ultralow attachment culture plate 
(Corning CoStar). For first generation M1 culturing, cells 
were grown with replenishment of the medium twice 
over 7 days. For second M2 generation culturing, M1 
mammospheres were harvested, incubated with trypsin 
for 3 min at 37°C, and mechanically dispersed by gentle 
pipetting. Single cells were confirmed under a microscope, 
counted and resuspended in fresh MammoCult™ medium. 
Mammospheres were visualized using a Nikon inverted 
TE2000 microscope and scored as positive when ≥50 µm 
in size. Sphere forming efficiency (SFE) was calculated 
by dividing the number of mammospheres by the number 
of suspended cells.
Chromatin immunoprecipitation (ChIP) assays.
 Soluble chromatin was prepared from 2-3 x 106 
cells as described [23] and precipitated with anti-NF-κB 
or a control nonimmune IgG. For re-ChIP assays, NF-
κB complexes from the primary ChIP were eluted and 
reimmunoprecipitated with anti-MUC1-C as described 
[23]. The SYBR green qPCR kit was used for ChIP qPCRs 
with the ABI Prism 7000 Sequence Detector (Applied 
Biosystems).  Relative  fold  enrichment  was  calculated 
as described [55]. Primers used for qPCR of the IL-8 
promoter and control region are listed in Supplemental 
Table S2. 
Assessment of tumorigenicity. 
MDA-MB-468/CshRNA  and  MDA-MB-468/
MUC1shRNA cells growing in log-phase cultures were 
trypsinized and washed twice with sterile PBS. Viable 
cells were determined by trypan blue exclusion. Cells 
(4 x 106) suspended in 0.2 ml sterile PBS were injected 
subcutaneously into the flanks of 4-6 week old female 
BALB/c nu/nu mice. Tumor volumes were calculated 
using the formula V=(L x W2)/2, where L and W are the 
larger and smaller diameters, respectively.
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